Repositioning of dexamethasone intravitreal implant (Ozurdex®) migrated into the anterior chamber

Ozurdex ® (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex ® into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical remova...

Full description

Saved in:
Bibliographic Details
Published inInternational ophthalmology Vol. 32; no. 6; pp. 583 - 584
Main Authors Vela, José I., Crespí, Jaume, Andreu, David
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 01.12.2012
Springer Nature B.V
Subjects
Aged
Anterior Chamber
Case Report
Dexamethasone - pharmacology
Drug Implants
Female
Foreign-Body Migration - diagnosis
Foreign-Body Migration - surgery
Glucocorticoids - pharmacology
Humans
Macular Edema - drug therapy
Medicine
Medicine & Public Health
Ophthalmology
Reoperation - methods
Vitreous Body
Complications
Dexamethasone intravitreal implant
Surgical technique
Ozurdex
Online AccessGet full text

Cover

More Information
Summary:Ozurdex ® (Allergan Inc., Irvine, CA, USA) is a biodegradable implant of dexamethasone (0.7 mg) injected into the vitreous cavity to treat macular oedema. We report a case of migration of Ozurdex ® into the anterior chamber in a patient who had a previous iris-claw lens implantation. Surgical removal of the implant was avoided due to the absence of anterior complications and the loss of effectiveness of the drug delivery system. Repositioning of the implant to the posterior segment is described. This case illustrates the efficacy of this technique in cases of migration into the anterior chamber in eyes without corneal decompensation.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0165-5701
1573-2630
DOI:10.1007/s10792-012-9604-7